Pharma Tech

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Jul 10, 2026, 9:31 AM

Read Full Article → Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Translate article text

Choose a language and wait for the translated text.

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.